Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 1.01, 3.01, 8.01, 9.01 · 8-K

NANO DIMENSION LTD

Entry into a Material Definitive Agreement · Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Other Events

Item 1.01 Entry into a Material Definitive Agreement. On February 2, 2026, Nano Dimension Ltd., a company incorporated under the laws of the State of Israel (the “Company,” “us,” “we” or “Nano”), entered into a Rights Agreement (the “Rights Agreement”) with The Bank of New York Mellon, as rights agent, to protect the interests of the holders of the Company’s American Depository Shares (each, an “A…

Filed Feb 3, 2026Accepted Feb 3, 2026, 6:13 AM ESTCIK 1643303Accession 0001104659-26-009481
Share

Company context

Nano Dimension Ltd. (Nasdaq: NNDM) has historically delivered advanced digital manufacturing technologies, including serving customers across the defense, aerospace, automotive, electronics and medical device industry segments. For more information, please visit https://www.nano-di.com/.

Current securities

Historical securities (2)

Recent company filings

  1. ARS filingNov 10, 2026
  2. DEF 14A filingNov 10, 2026
  3. 10-Q filingNov 5, 2026
  4. Results of Operations and Financial Condition · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsNov 5, 2026
  5. 3 filingOct 26, 2026

Registered securities in this filing

NANO DIMENSION LTD. · 8-K · Filed 2026-02-03

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

American Depositary Shares

Symbol
NNDM
Exchange
NASDAQ
Classification
ADS
Status
Current
Filing context

Context: From2026-02-022026-02-02_custom_AmericanDepositarySharesMember

Dimensions: us-gaap:StatementClassOfStockAxis

Rights to Purchase American Depositary Shares

Symbol
NNDM
Exchange
NASDAQ
Classification
RIGHT
Status
Current
Filing context

Context: From2026-02-022026-02-02_custom_RightsToPurchaseAmericanDepositarySharesMember

Dimensions: us-gaap:StatementClassOfStockAxis

Accession 000110465926009481 · 2 registered-security cover members

Read the exact SEC filing ↗

Disclosure sections

Items 1.01, 3.01, 8.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 1.01Item 1.01 - Entry into Material Agreement
Item 1.01 Entry into a Material Definitive Agreement. On February 2, 2026, Nano Dimension Ltd., a company incorporated under the laws of the State of Israel (the “Company,” “us,” “we” or “Nano”), entered into a Rights Agreement (the “Rights Agreement”) with The Bank of New York Mellon, as rights agent, to protect the interests of the holders of the Company’s American Depository Shares (each, an “ADS” and collectively, “ADSs”). The Rights Agreement, if triggered, will significantly dilute the ownership of any Acquiring Person (as defined below). The Board of Directors of the Company (the “Board”) believes the Rights Agreement is an effective course of action for the Board to fulfill its fiduciary duties to the Company and to enable ADS holders to realize the long-term value of their investment. The Rights Agreement was adopted following a careful evaluation and consultation with the Company’s external advisors. The adoption of the Rights Agreement is not intended to prevent or interfere with any action with respect to Nano that the Board determines to be in the best interests of the Company. Instead, it will position the Board to fulfill its fiduciary duties by ensuring that the Board has sufficient time to make informed judgments about any attempts to control or significantly influence the Company. The Rights Agreement will encourage anyone seeking to gain a significant interest in Nano to negotiate directly with the Board prior to attempting to control or significantly influence the Company. Further to those goals, the Rights (as defined below) may cause substantial dilution to a person or group that acquires beneficial ownership of 9.99% or more of the ordinary shares then outstanding, par value NIS 5.00 per share, of the Company (“Ordinary Shares”). We provide a summary of the terms of the Rights Agreement below. The below description is only a summary and is qualified in its entirety by reference to the full text of the Rights Agreement, a copy of which is filed as Exhibit 4.1 to this Current Report on Form 8-K (the “Form 8-K”). Summary of the Rights Agreement The Rights; Rights Agreement The Board has authorized, pursuant to the Rights Agreement, the issuance of one special purchase right (a “Right”) for each ADS, each ADS representing one Ordinary Share, outstanding at the close of business on February 13, 2026. The Rights will initially trade with, and will be inseparable from, the corresponding ADSs. The Rights are evidenced only by the balances indicated in the ADS register maintained by The Bank of New York Mellon (the “Depositary”) with respect to uncertificated ADSs or, in the case of certificated ADSs, the certificates that evidence those ADSs. New Rights will accompany any new ADSs that are issued from February 13, 2026 until the earliest of the Distribution Record Date, the Redemption Date and the Final Expiration Date (as defined below). The Rights will be issued pursuant to a Rights Agreement, dated as of February 2, 2026 (the “Rights Agreement”), by and between the Company and The Bank of New York Mellon, in its capacity as rights agent (the “Rights Agent”). Capitalized terms used in this Form 8-K but not otherwise defined herein have the meanings given to them in the Rights Agreement. Each Right will allow its holder to purchase from the Company one (1) ADS, at a purchase price of $0.01 per ADS, once the Rights become exercisable. Prior to exercise, the Right does not give its holder any dividend, voting, or liquidation rights or other rights as an ADS holder of the Company. Exercisability The Rights will not be exercisable until the Company, after consultation with the Rights Agent, determines the distribution date for the Rights which shall be as soon as practicable after the earlier of: (a) the Close of Business on the tenth (10th) day after the public announcement or public disclosure that a person or group has become an “Acquiring Person” by obtaining beneficial ownership of 9.99% or more of the Company’s outstanding Ordinary Shares (subject to the parameters and exceptions described below and in the Rights Agreement, an “Acquiring Person”), except if such person or group has become an Acquiring Person pursuant to an offer approved by the Board; or (b) the Close of Business on the tenth (10th) day (or a date determined by the Board before any person or group becomes an Acquiring Person) after a person or group consummates a tender or exchange offer (except if such person or group has become an Acquiring Person pursuant to an offer approved by the Board) which, if consummated, would result in that person or group becoming an Acquiring Person. The earlier of such dates, upon which the Rights become exercisable, is referred to as the “Distribution Record Date”. A Person shall not be deemed to beneficially own any security if any agreement, arrangement or understanding pursuant to which such Person has the right to vote such security (1) arises solely from a revocable proxy or consent given to such Person in response to a public proxy or consent solicitation made pursuant to, and in accordance with, the applicable rules and regulations promulgated under the Exchange Act of 1934, as amended (the “Exchange Act”), including the disclosure requirements of Schedule 14A thereunder, and (2) is not also then reportable on Schedule 13D under the Exchange Act (or any comparable or successor report). Until the Distribution Record Date, the balances in the register maintained by the Depositary with respect to uncertificated ADSs or, in the case of certificated ADSs, the certificates evidencing those ADSs will also evidence the Rights, and any transfer of ADSs will also constitute a transfer of Rights. After the Distribution Record Date, the Rights will separate from the ADSs and be evidenced solely by entries in the register maintained by the Rights Agent, or, in the case of certificated Rights, by Right certificates. Any Rights held by an Acquiring Person or any Associate or Affiliate thereof are void and may not be exercised. Consequences of a Person or Group Becoming an Acquiring Person If a person or group becomes an Acquiring Person, then beginning on the Distribution Record Date, all holders of Rights except the Acquiring Person or any Associate or Affiliate thereof may, for a purchase price of $0.01 per one ADS, purchase one (1) ADS. If the Company is later acquired in a merger or similar transaction after the Distribution Record Date, each holder of a Right except the Acquiring Person or any Associate or Affiliate thereof may, for a purchase price of $0.01 per ADS, purchase, in lieu of ADSs representing Ordinary Shares, one (1) times the number of securities of the acquiring corporation, that each ADS holder of the Company is entitled to for each Ordinary Share. Scope of “Acquiring Person” Definition An “Acquiring Person” is any Person who or which, together with all Affiliates and Associates of such Person, shall be the Beneficial Owner of 9.99% or more of the Ordinary Shares of the Company then outstanding, but shall not include the Company, any Subsidiary of the Company, any shares issued and/or issuable pursuant to a Permitted Offer or under a benefit or share ownership plan of the Company or any Subsidiary of the Company, or any entity holding Ordinary Shares for or pursuant to the terms of any such plan. Notwithstanding the foregoing, no Person shall become an “Acquiring Person” as the sole result of an acquisition of Ordinary Shares by the Company which, by reducing the number of Ordinary Shares of the Company outstanding, increases the proportionate number of Ordinary Shares of the Company beneficially owned by such Person to 9.99% or more of the Ordinary Shares of the Company then outstanding; provided, however, that, if a Person shall become the Beneficial Owner of 9.99% or more of the Ordinary Shares of the Company then outstanding by reason of share purchases by the Company and shall, after such share purchases by the Company, become the Beneficial Owner of any additional Ordinary Shares of the Company, then such Person shall be deemed to be an Acquiring Person. Notwithstanding the foregoing, if the Board determines in good faith that a Person who would otherwise be an Acquiring Person has become such inadvertently, and such Person divests as promptly as practicable a sufficient number of Ordinary Shares, so that such Person would no longer be an Acquiring Person, as defined pursuant to the foregoing provisions of this paragraph, then such Person shall not be deemed to be an Acquiring Person for any purposes of the Rights Agreement. A “Permitted Offer” means an offer to purchase securities of the Company or a transfer of securities of the Company, that the Board has determined is both adequate and otherwise in the best interests of the Company. Redemption and Termination The Board may, at its option, at any time prior to such time that any Person becomes an Acquiring Person, for no consideration, redeem all but not less than all the then outstanding Rights (the effective date of redemption, the “Redemption Date”). The redemption of the Rights by the Board may be made effective at such time, on such basis and with such conditions as the Board, in its sole discretion, may establish. Immediately upon the effectiveness of the action of the Board ordering the redemption of the Rights, and without any further action and without any notice, the right to exercise the Rights will terminate and the Company may terminate the Rights Agreement. Exchange The Board may, at its option, at any time after any Person becomes an Acquiring Person, determine, and instruct the Rights Agent, to exchange all or part of the then outstanding and exercisable Rights (except for Rights that have become void) for ADSs at an exchange ratio of one (1) ADS per Right, appropriately adjusted to reflect any adjustment in the number of Rights (the “Exchange Ratio”). However, the Board will not be empowered to effect such exchange at any time after any Person (other than the Company, any Subsidiary of the Company, any employee benefit or stock ownership plan of the Company or any such Subsidiary, or any entity holding Ordinary Shares for or pursuant to the terms of any such plan), together with all Affiliates and Associates of such Person, becomes the Beneficial Owner of 50% or more of the Ordinary Shares then outstanding. Immediately upon the action of the Board ordering the foregoing exchange, the right to exercise the Rights that are to be exchanged will terminate and the only right thereafter of a holder of such Rights shall be to receive that number of ADSs equal to the number of such Rights held by such holder multiplied by the Exchange Ratio. In the event that there shall not be sufficient Ordinary Shares issued but not outstanding or authorized but unissued to permit any exchange of Rights, the Company will take all such action as may be necessary to authorize additional Ordinary Shares for issuance upon exchange of the Rights. Compliance with Law The Rights Agreement shall not be deemed as limiting the Board from taking any actions (or refraining from taking any actions), which the Board reasonably believes are required to adhere with applicable law, including without limitations, The Israeli Companies Law, and any applicable fiduciary duties. Anti-Dilution Provisions The Board may adjust the purchase price of the ADSs, the number of ADSs issuable and the number of outstanding Rights to prevent dilution that may occur from a share dividend, a share split, or a reclassification of the Ordinary Shares or ADSs. No adjustments to the exercise price of less than 1% will be made. Amendments The terms of the Rights Agreement may be amended by the Board without the consent of the holders of the Rights. After a person or group becomes an Acquiring Person, the Board may not amend the Rights Agreement in a way that adversely affects holders of the Rights. Expiration The Rights will expire on February 1, 2027 (the “Final Expiration Date”).
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events. On February 2, 2026, the Company announced the adoption of the Rights Agreement, a copy of which is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
Filed exhibits (1)
EX-99.1 (by filename) tm264887d1_ex99-1.htm

Exhibit 99.1 Nano Dimension Adopts Limited Duration Shareholder Rights Agreement Waltham, Mass., February 2, 2026 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (Nasdaq: NNDM) (“Nano Dimension” or the “Company”), a leader in digital manufacturing solutions, today announced that its Board of Directors (the “Board”) has adopted a limited duration shareholder rights agreement (the “Rights Agreement”). The adoption of the Rights Agreement is intended to protect the long-term interests of Nano Dimension and all Nano Dimension’s holders of American Depository Shares (“ADSs”) and enable them to realize the full potential value of their investment in the Company. The Rights Agreement is designed to reduce the likelihood that any entity, person or group would gain control of, or exert significant influence over, Nano Dimension. The Rights Agreement is not intended to prevent or interfere with any action with respect to Nano Dimension that the Board determines to be in the best interests of the Company. Instead, it will assist the Board with fulfilling its fiduciary duties to the Company by ensuring that the Board has sufficient time to make informed judgments about any attempts to gain control…

Open exhibit ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.